|
Volumn 15, Issue 7, 2009, Pages 890-891
|
Defining Conditioning Regimens for BMT-Recognition of "Regimens of Intermediate Intensity"
a,b a,b a,b |
Author keywords
[No Author keywords available]
|
Indexed keywords
ALEMTUZUMAB;
CARMUSTINE;
CYTARABINE;
ETOPOSIDE;
FLUDARABINE;
MELPHALAN;
THYMOCYTE ANTIBODY;
ALLOGENEIC STEM CELL TRANSPLANTATION;
ALLOGENIC BONE MARROW TRANSPLANTATION;
BONE MARROW TRANSPLANTATION;
CANCER COMBINATION CHEMOTHERAPY;
CLINICAL TRIAL;
DRUG EFFICACY;
HEMATOLOGIC MALIGNANCY;
HODGKIN DISEASE;
HUMAN;
INTERMETHOD COMPARISON;
LETTER;
MANTLE CELL LYMPHOMA;
MYELOABLATIVE CONDITIONING;
REDUCED INTENSITY CONDITIONING;
TREATMENT OUTCOME;
HEMATOPOIETIC STEM CELL TRANSPLANTATION;
HUMANS;
RETROSPECTIVE STUDIES;
TRANSPLANTATION CONDITIONING;
|
EID: 67349133132
PISSN: 10838791
EISSN: 15236536
Source Type: Journal
DOI: 10.1016/j.bbmt.2009.02.012 Document Type: Letter |
Times cited : (2)
|
References (4)
|